



Haspin: a promising target for the design of inhibitors as potent anticancer drugs

Reviews • POST-SCREEN

Nathalie Gisèle Amoussou^{1,2}, André Bigot³, Christos Roussakis¹ and Jean-Michel H. Robert¹

¹ Université de Nantes, Nantes Atlantique Universités, Cibles et Médicaments du Cancer et de l'Immunité IICiMed-AE1155, Institut de Recherche en Santé 2, 22, rue Bénoni-Goulin, F-44000 Nantes, France

² Université d'Abomey-Calavi, Faculté des Sciences de la Santé, Laboratoire de Chimie Pharmaceutique Organique, 01 BP 188 Cotonou, Benin

³ Université d'Abomey-Calavi, Faculté des Sciences de la Santé, Unité d'Enseignement et de Recherche en Immunologie, 01 BP 188 Cotonou, Benin

Protein kinases constitute a large group of enzymes in eukaryotes and have an important role in many cellular processes. Several of these proteins are active kinases, such as haploid germ cell-specific nuclear protein kinase (Haspin), an atypical eukaryotic protein kinase that lacks sequence similarity with other eukaryotic protein kinases. Haspin is a serine/threonine kinase that associates with chromosome and phosphorylates threonine 3 of histone 3 during mitosis. Haspin overexpression or deletion results in defective mitosis. It has been shown that Haspin inhibitors have potent anti-tumoral effects. Given that the only Haspin substrate is threonine 3 of histone 3, inhibition of Haspin might have fewer adverse effects compared with XXXX. Here, we highlight the chemical structures and actions of currently known Haspin inhibitors.

Introduction

The protein kinases constitute a large group of enzymes in eukaryotes. These enzymes catalyse the transfer of the γ -phosphate of ATP (or GTP) to generate phosphate monoesters using the hydroxyl groups of many proteins. Depending on the proteins involved, this reaction results in either serine/threonine kinases or tyrosine kinases. These protein kinases are related by virtue of their homologous kinase domains and have important roles in many cellular processes (e.g., proliferation, gene expression, metabolism, motility, membrane transport, apoptosis, etc.); unsurprisingly, their misregulation often results in disease. Most eukaryotic protein kinases are members of the eukaryotic protein kinase superfamily. The kinase domain of protein kinases (250–300 amino acids) contains 12 conserved subdomains. The crystal structure of eukaryotic protein kinases shows that they have a bilobed structure (the smaller *N*-terminal lobe and the larger *C*-terminal lobe). The deep cleft between the two lobes is recognised as the site of catalysis. Three functions are attributed to the kinase domain:

(i) binding and orientation of the ATP (or GTP) phosphate donor as a complex with the divalent cation; (ii) binding and orientation of the protein substrate; and (iii) transfer of the γ -phosphate from the ATP to the hydroxyl residue of the protein substrate [1,2]. In 1995, Hanks and Hunter proposed the first classification of eukaryotic protein kinases, based on their structural and functional properties [2]. In 2002, the classification was refined by Manning *et al.* based on the extracatalytic sequence similarity and biological function [3]. Several protein kinases lack sequence similarity with eukaryotic protein kinases and, thus, have been classified as inactive pseudokinases [3].

Haploid germ cell-specific nuclear protein kinase (Haspin) proteins are divergent members of the eukaryotic protein kinase family. Haspin (encoded by germ cell-specific gene 2: *Gsg2*) is found in many eukaryotic lineages (animal, fungi, and plants), and the protein and its mRNA were initially detected in male germ cells [4]. All proliferating cell lines express Haspin mRNA, and it has been detected in thymus, bone marrow, and foetal liver and, more weakly, in spleen, intestine, lung, and a variety of fetal tissues. Its expression is correlated with tissues that have

Corresponding author: Robert, J.H. (jean-michel.robert@univ-nantes.fr)

GLOSSARY

Budding uninhibited by benzimidazole 1 (Bub1) and budding uninhibited by benzimidazole-related 1 kinases (BubR1): serine/threonine checkpoint kinases with important roles as kinetochore-microtubule attachment regulators.

Centromere protein A (CENP-A): a centromere-interacting protein (along with CENP-B, CENP-C1, CENP-D, CENP-E and CENP-F).

CDC2-like kinase 1 (CLK1): has an important role in the regulation of RNA splicing through phosphorylation of members of the serine and arginine-rich (SR) family of splicing factors.

Chromosomal passenger complex (CPC): comprises Aurora B, INCENP, Borealin, and Survivin; a key orchestrator protein of orderly mitotic exit and cytokinesis.

DYRK(1A, 1B, 2, 3): members of the dual specificity tyrosine-phosphorylation-regulated kinase family.

Highly expressed protein in cancer 1 (Hec1): located at the centromere during cell mitosis; has an important role in the spindle checkpoint pathway.

Protein kinase Ac (PKAc): catalytic subunit of cAMP-dependent protein kinase.

Repo-Man: nuclear protein that is a specific regulatory subunit for PP1 γ . Repo-Man disperses in the cytoplasm as cells enter prophase but relocalises to chromatin at anaphase onset. Repo-Man was identified as a complex responsible for inactivation of a regulator of chromosome architecture in anaphase.

Spindle assembly checkpoint (SAC): sometimes referred to as the 'mitotic checkpoint' or 'M-phase checkpoint'; a quality-control mechanism that prevents anaphase until all the chromosomes are stably attached to the spindle.

significant levels of cellular proliferation and differentiation [5]. Studies have confirmed Haspin as a serine/threonine kinase and a constitutively active enzyme.

Studies have shown that, during interphase, Haspin is autoinhibited by a conserved segment of basic residues (the Haspin basic inhibitory segment; HBIS) within the N-terminal domain, immediately upstream of the kinase domain. The kinase is reactivated in M phase by Cdk1 phosphorylation of the N terminus (Fig. 1). This phosphorylation leads to recruitment of Polo-like kinase-1 (Plk-1), which in turn further phosphorylates multiple sites at the N-terminal domain of Haspin. In addition, in human cells, the localisation of Aurora B kinase to the centromere creates a positive feedback loop that increases Haspin activity [6].

The crystal structure of Haspin reveals at least four peculiarities [5]: (i) the N-terminal lobe is entirely buried under an additional layer created by an N-terminal extension and two insertions; (ii) reorganisation of the activation segment contributes to the creation of an unusual substrate-binding site; (iii) an additional insertion between the β 7 and β 8 loop that contains two β -strands; and (iv) deletion of the α G helix.

During mitosis, Haspin localises predominantly to condensed chromosomes during mitosis, to centrosomes following nuclear envelope breakdown (NEBD), to spindle microtubules during metaphase, and to the midbody during telophase. The only known substrate of Haspin is histone H3. During mitosis, Haspin

phosphorylates histone H3 at threonine 3 to form H3T3 ph [7]. Phosphorylated threonine 3 is detected on condensing chromosomes during prophase, prometaphase, and metaphase, is decreased during anaphase and is absent during telophase. Histone H3T3 ph creates a chromatin-binding site for survivin and recruits the **chromosomal passenger complex** (CPC; see Glossary) at inner centromeres during mitosis [8–12]. Haspin activity facilitates the activation of Aurora B, a member of the CPC (Fig. 2). Aurora B kinase activity is necessary for full phosphorylation of Haspin during mitosis and stimulates H3T3 phosphorylation. It also acts to generate a positive feedback between Haspin and Aurora B and allows CPC accumulation on chromatin during mitosis [13]. The complex protein phosphatase 1 γ (PP1 γ)/**Repo-Man** induces indirect inhibition of XXXX by Q5 dephosphorylating of H3T3 at the end of mitosis [14,15].

Haspin overexpression or deletion results in defective mitosis. Inhibition of Haspin prevents normal chromosome alignment at metaphase, while Haspin overexpression results in a delay before metaphase. In addition, Haspin depletion leads to the loss of the cohesion association and activation of the spindle checkpoint, arresting mitosis in a prometaphase-like state [16].

Haspin inhibitors have antimitotic effects and might have fewer adverse effects than XXXXX because Haspin has only one known substrate (Thr 3 of histone 3) [17]. A previous study showed that Haspin inhibitors cause the displacement of Aurora B from inner centromeres, resulting in its diffuse distribution on chromatin [17]. Therefore, XXXXXXX.

Q6

Haspin inhibitors**Acridine derivatives**

Using high-throughput screening (HTS), the compound LDN-192960, an acridine derivative, was identified as a potent kinase Haspin inhibitor with IC_{50} = 0.01 MM (Fig. 3) [18]. Based on the structure–activity relationships (SAR) of the acridine series, Cuny *et al.* [19] identified many Haspin inhibitors, the general structure of which is given in Fig. 3. All compounds showed good inhibitory activity against Haspin, while compound LDN-209929 was very selective for Haspin (180-fold selectivity versus **DYRK2**). LDN-209929 was reported to compromise the spindle checkpoint during mitosis when microtubules are severely disrupted [17]. However, the adverse effects highlighted with either acridine or tacrine, for example, do not support the use of this scaffold in the development of drugs for use in humans.

Beta carboline derivatives**Harmine and harmalol**

Harmine is an indole alkaloid from the plant *Peganum harmala* with the pyrido[3,4-b]indole ring structure characteristic of β -carboline family alkaloids (Fig. 3), which includes harmaline, harman, and harmalol. These compounds exhibit psychoactive activity on the central nervous system (CNS), with hallucinogen adverse effects. Harmine has also been identified as an inhibitor of DYRK family kinases, with IC_{50} values of 0.03–0.35 MM reported for DYRK1A, and approximately 50-fold lower potency toward DYRK2 [20–23]. More recently, using time-resolved fluorescence resonance energy transfer (TR-FRET), Cuny *et al.* showed harmine and harmalol to be moderately potent Haspin inhibitors, with IC_{50} values of 0.59 and 0.77 MM, respectively [24]. The adverse effects




FIGURE 1

Q9 Title. During interphase, the histone H3T3 kinase haploid germ cell-specific nuclear protein kinase (Haspin) is autoinhibited by a basic segment (Haspin basic inhibitory segment; HBIS). At the start of mitosis, Haspin undergoes priming phosphorylation of its N terminus by Cdk1, resulting in recruitment of polo-like kinase 1 (Plk1), which phosphorylates multiples sites at the Haspin N terminus, activating the protein.

of these compounds on the CNS limit interest in their use as therapeutics, although this structure could provide a useful scaffold for the design of optimised drug-candidates.


LDN-211898 and related compounds

In a SAR study of beta-carboline derivatives and by using the results of SAR studies carried out with the acridine series, compound LDN-211898 (Fig. 3) was identified as a lead compound. This compound has an IC_{50} value for Haspin of 0.10 μ M and was very selective for Haspin (150-fold selectivity versus DYRK2) [24]. This study confirmed the beta-carboline scaffold as pharmacophoric structure that could be useful for the design of Haspin inhibitors. Interestingly, the lack of strict specificity towards Haspin (observed for LDN-211898 and some related compounds) could be advantageous, leading to compounds targeting simultaneously several kinases with an essential role during cell division.

Ribofuranosyl derivatives

5-ITu Initially, 5-iodo-7- β -D-ribofuranosyl-7H-pyrrolo[2,3-d]pyr-imidin-4-amine (5-ITu; Fig. 4) was characterised as an adenosine kinase inhibitor by Wotring and Townsend [25]. Recently, it was demonstrated that 5-ITu, with an IC_{50} of 5–9 nM, has potent and selective inhibitory activity against Haspin *in vitro* [26–29]. 5-ITu targets the ATP-binding site of Haspin and causes dose-dependant displacement of the CPC subunits [17,29]. 5-ITu also compromised chromosome

alignment and caused a dose-dependant decrease in mitotic (phospho)-protein monoclonal-2 phosphoepitopes. According to De Antoni *et al.*, 5-ITu potently inhibited Haspin but not Aurora B *in vitro*, and counteracted the centromeric localisation of the CPC without affecting the bulk of Aurora B activity in HeLa cells. Mislocalisation of Aurora B correlated with dephosphorylation of **Centromere protein A (CENP-A)**, **Highly expressed protein in cancer 1 (Hec1)**, and **spindle assembly checkpoint (SAC)** override. In addition, 5-ITu impaired kinetochore recruitment of the mitotic checkpoint serine/threonine-protein kinases **Budding uninhibited by benzimidazole 1 (Bub1)** and **budding uninhibited by benzimidazole-related 1 kinases (BubR1)**, an effect that was reversed by concomitant inhibition of phosphatase activity. Forcing localisation of Aurora B to centromeres in 5-ITu also restored Bub1 and BubR1, but failed to rescue the SAC override. These results suggest that Haspin is required for a part of SAC signaling that is distinct from the centromere and kinetochore localisation of Aurora B and other proteins, whose localisation is Aurora B dependent; however, 5-ITu might inhibit a distinct SAC pathway in addition to that represented by the Haspin–Aurora B axis [29]. Thus, 5-ITu appears to be a useful tool for chemical biology investigations of Haspin activity in tumour development. However, the 'iodine' nature of the molecule could result in adverse effects related to thyroid metabolism

**FIGURE 2**

Title. The nucleosome comprises four core histone proteins (H2A, H2B, H3, and H4) and is the primary building block of chromatin. Histone H3, one of the main histone proteins involved in chromatin in eukaryotic cells, has conserved N-terminal tail residues that undergo different post-translational modifications, such as phosphorylation. Four residues within the H3 N terminus are phosphorylated during mitosis: Thr3, Ser10, Thr11 and Ser28. Phosphorylation at Thr3, which is highly conserved among many species, is catalysed by Haspin and provides a chromatin-binding site for the recruitment of the chromosomal passenger complex (CPC). Aurora B, one of the four constituents of CPC, along with Survivin, Borealin and INCENP, phosphorylates Haspin, which creates a signal amplification loop. This contributes to CPC accumulation at centromeres and regulates mitosis and chromosome segregation. Haspin is then dephosphorylated by the protein phosphatase 1 γ (PP1 γ)/Repo-Man complex.

and, therefore, it is difficult to envisage such an iodo-scaffold being used in the design of molecules of clinical interest.

CHR-6494

Compound 3-(1H-indazol-5-yl)-N-propylimidazo[1,2-b]pyridazin-6-amine (CHR-6494; Fig. 4) is a first-in-class Haspin inhibitor identified by HTS for kinase inhibitors, rather than being identified from a rational drug design strategy. This Haspin-selective inhibitor has an IC_{50} value of 2 nM and inhibited cancer cell growth dose dependently (473 nM for HeLa, 500 nM for HCT-116 and 752 nM for MDA-MB-231 cells). The compound also blocked H3T3 ph, resulting in an abnormal mitotic spindle and a large defect in chromosomal alignment and centrosomes. It also upregulated Bub1 and cyclin B1 and potentially induced arrest in G2/M and subsequent apoptosis. In addition, CHR-6494 efficiently blocked basic fibroblast growth factor (bFGF)-induced vessel sprouting (by 70% at 1 μ M in a chicken embryo aortic arch ring assay) and suppressed tumor growth in a HCT-116 xenografted mouse model (50 mg/kg, intraperitoneally) [30].

CHR-6494 appears to be a member of a new generation of antimitotic drugs targeting mitotic machinery other than microtubules, avoiding some of the adverse effects associated with, for example, taxanes, which occur because of the role of tubulin in many cellular functions in addition to mitosis. Thus, CHR-6494 constitutes an interesting tool for use in biological and antitumor investigations in addition to drug design,

although further studies of its pharmacokinetic profile are required.

ARC-type bisubstrate inhibitors

Adenosine analogue-oligoarginine conjugate (ARC)-type bisubstrate inhibitors have been used in studies that involve the construction of chimeric structures (Fig. 4) comprising a fragment (nucleoside mimic) binding to the ATP-site of Haspin and a histone H3(1-7) peptide binding to the protein substrate site of a protein kinase, conferring the selectivity of these conjugates to this target [31]. The main expected advantage of bisubstrate inhibitors is their potential ability to generate more interactions with the target enzyme that could result in improved affinity and selectivity of the conjugates; several research groups have used this bisubstrate approach for the design and synthesis of inhibitors of various protein kinases [32].

As the nucleoside mimic section of these compounds, 5-ITu-like scaffolds were chosen, such as adenosine-4'-dehydroxymethyl-4'-carboxylic acid (Adc), 5-(2-aminopyrimidin-4-yl)-thiophene carboxylic acid (AMTH), and 6-aminohexanoic acid (Ahx). Based on this model, Uri and co-workers designed and developed first-generation ARC-type inhibitors of protein kinases, such as HER2, Aurora, CDK ROCK, or PIM-1, resulting in the identification of the reference compound ARC-902 (Fig. 4). More recently, studies on the Haspin/Histone H3 (1-7) co-crystal predicted two positions in the structure of the Histone H3(1-7) peptide to which nucleoside




FIGURE 3 Chemical structures of (a) acridine and (b) β -carboline compounds.

mimics could be linked [33]. The first position is located near the N terminus of peptide and the second near to the phosphorylatable residue, Thr3.

These two aspects of this strategy resulted in the identification of two related series of new potent disubstrate inhibitors of protein kinases, with a specific approach for targeting Haspin leading to the identification of ARC-3354 (Fig. 4) as lead compound. ARC-3354 has a subnanomolar K_d value toward Haspin and a 90-fold higher affinity toward Haspin than towards **protein kinase Ac** (PKAc), the basophilic reference kinase [31].


However, despite an excellent affinity and selectivity profile determined by *in vitro* evaluation, these compounds suffer an absence of data concerning their membrane-penetrative capability as well as their pharmacokinetics. Moreover, the peptidic character of these inhibitors could limit their development as drug candidates and, consequently, their therapeutic interest.

Concluding remarks

The cell cycle is an elaborate and evolutionarily conserved process in actively proliferating cells. Given that cell cycle aberrations are a hallmark of cancer, mitosis has been the target of anticancer

strategies for decades; however, despite numerous mitosis-selective drug discovery strategies (e.g., microtubule-targeting agents, antimetabolic kinases, and antimetabolic proteins; Table 1) and ensuing clinical trials, mitosis-targeted anticancer therapies have generally failed to translate their preclinical efficacy into clinical responses in human trials owing, in particular, to undesirable effects on nonproliferating cells and the emergence of drug resistance.

Here, we have discussed the development of inhibitors of Haspin, a serine/threonine kinase and a divergent member of the eukaryotic protein kinase family. During the past decade, many Haspin inhibitors have been identified and have validated this kinase as a target for anticancer drugs. Structures of Haspin inhibitors are very divergent but the established SARs and structure-selectivity relationships will be useful for the development of high-affinity Haspin inhibitors. These inhibitors could have potential therapeutic utility in cancer, with fewer adverse effects. In addition, such inhibitors could be combined with other mitosis-targeting drugs, to boost clinical efficacy. In addition, the key role of Haspin in many cellular processes and its important interactions with other mitotic kinases (e.g., Aurora B, Cdk1, Plk1, DYRKs, etc.) justifies the design of multitargeted mitosis inhibitors, in



Drug Discovery Today

FIGURE 4: Chemical structures of other chemical families of haploid germ cell-specific nuclear protein kinase (Haspin) inhibitors.

TABLE 1

Targeting the cell cycle in cancer: an overview of validated and emerging strategies

| Phase of cell cycle | Targets | |
|-----------------------|--|---|
| | Validated | Potential |
| Prophase | Cdk1, Aurora A, Plk1 | Plk4, NEKs |
| Prometaphase | Microtubule-targeting agents, Cdk1, Aurora A, Aurora B, Plk1 | Microtubule-associated Ser/Thr kinase-like, Human monopolar spindle (MPS1) kinase, Haspin |
| Metaphase | Microtubule-targeting agents, Aurora B | MPS1, Bub1, BubR1, NEKs, Haspin |
| Anaphase | N/A | Kinesin, Separase |
| Telophase/Cytokinesis | Aurora B, Plk1 | Kinesin |

accordance with biological and clinical observations that inhibition of a small number of pertinent targets can be more efficient than the complete inhibition of a single target in cancer therapy. This could also lead to a new generation of anticancer compounds

that reduces the number of co-administered drugs required per patient.

References

- Hanks, S.K. (1991) Eukaryotic protein kinases. *Curr. Opin. Struct. Biol.* 1, 369–383
- Hanks, S.K. and Hunter, T. (1995) The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. *FASEB J.* 9, 576–596
- Manning, G. *et al.* (2002) The protein kinase complement of the human genome. *Science* 298, 1912–1934
- Tanaka, H. *et al.* (1994) Isolation and characterization of cDNA clones specifically expressed in testicular germ cells. *FEBS Lett.* 355, 4–10

- 5 Villa, F. *et al.* (2009) Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization. *Proc. Natl. Acad. Sci. U. S. A.* 106, 20204–20209
- 6 Ghenoiu, C. *et al.* (2013) Autoinhibition and Polo-dependent multisite phosphorylation restrict activity of the histone H3 kinase Haspin to mitosis. *Mol. Cell* 52, 734–745
- 7 Dai, J. *et al.* (2005) The kinase Haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. *Genes Dev.* 19, 472–488
- 8 Wang, F. *et al.* (2010) Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. *Science* 330, 231–235
- 9 Kelly, A.E. *et al.* (2010) Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. *Science* 330, 235–239
- 10 Bekier, M.E. *et al.* (2015) Borealin dimerization mediates optimal CPC checkpoint function by enhancing localization to centromeres and kinetochores. *Nat. Commun.* 6, 6775
- 11 Trivedi, P. and Stukenberg, P.T. (2016) A centromere-signaling network underlies the coordination among mitotic events. *Trends Biochem. Sci.* 41, 160–174
- 12 Lara-Gonzalez, P. *et al.* (2012) The spindle assembly checkpoint. *Curr. Biol.* 22, R966–R980
- 13 Wang, F. *et al.* (2011) A positive feedback loop involving haspin and aurora B promotes CPC accumulation at centromeres in mitosis. *Curr. Biol.* 21, 1061–1069
- 14 Qian, J. *et al.* (2011) PP1/Repo-Man dephosphorylates mitotic histone H3 at T3 and regulates chromosomal Aurora B targeting. *Curr. Biol.* 21, 766–773
- 15 Vagnarelli, P. *et al.* (2011) Repo-Man coordinates chromosomal reorganization with nuclear envelope reassembly during mitotic exit. *Dev. Cell* 21, 328–342
- 16 Dai, J. *et al.* (2006) Regulation of mitotic chromosome cohesion by haspin and aurora B. *Dev. Cell* 11, 741–750
- 17 Wang, F. *et al.* (2012) Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation. *J. Cell. Biol.* 199, 251–268
- 18 Patnaik, D. *et al.* (2008) Identification of small molecule inhibitors of the mitotic kinase Haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. *J. Biomol. Screen.* 13, 1025–1034
- 19 Cuny, G.D. *et al.* (2010) Structure-activity relationship study of acridine analogs as Haspin and DYRK2 kinase inhibitors. *Bioorg. Med. Chem. Lett.* 20, 3491–3494
- 20 Bain, J. *et al.* (2007) The selectivity of protein kinase inhibitors: a further update. *Biochem. J.* 408, 297–315
- 21 Scifert, A. *et al.* (2008) DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine. *FEBS J.* 275, 6268–6280
- 22 Göckler, N. *et al.* (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. *FEBS J.* 276, 6324–6337
- 23 Ogawa, Y. *et al.* (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. *Nat. Commun.* 1, 86
- 24 Cuny, G.D. *et al.* (2012) Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. *Bioorg. Med. Chem. Lett.* 22, 2015–2019
- 25 Wotring, L.L. and Townsend, L.B. (1979) Study of the cytotoxicity and metabolism of 4-amino-3-carboxamido-1-(β -D-ribofuranosyl)pyrazolo[3, 4-d]pyrimidine using inhibitors of adenosine kinase and adenosine deaminase. *Cancer Res.* 39, 3018–3023
- 26 Fedorov, O. *et al.* (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. *Proc. Natl. Acad. Sci. U. S. A.* 104, 20523–20528
- 27 Eswaran, J. *et al.* (2009) Structure and functional characterization of the atypical human kinase haspin. *Proc. Natl. Acad. Sci. U. S. A.* 106, 20198–20203
- 28 Balzano, D. *et al.* (2011) A General framework for inhibitor resistance in protein kinases. *Chem. Biol.* 18, 966–975
- 29 De Antoni, A. *et al.* (2012) A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. *J. Cell. Biol.* 199, 269–284
- 30 Huertas, D. *et al.* (2012) Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. *Oncogene* 31, 1408–1418
- 31 Kestav, K. *et al.* (2015) Bisubstrate inhibitor approach for targeting mitotic kinase Haspin. *Bioconjug. Chem.* 26, 225–234
- 32 Lavogina, D. *et al.* (2010) Bisubstrate inhibitors of protein kinases: from principle to practical applications. *Chem. Med. Chem.* 5, 23–34
- 33 Uri, A. *et al.* (2010) Bisubstrate fluorescent probes and biosensors in binding assays for HTS of protein kinase inhibitors. *Biochim. Biophys. Acta* 1804, 541–546